Chemotherapy before and after surgery for high-risk pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer).
- Your cancer is considered high-risk but can still be removed with surgery.
- You have not had any prior treatment for pancreatic cancer, such as chemotherapy or radiation.
- Your overall health is good (able to do daily activities without major help), and your blood counts, liver, and kidney function are within acceptable ranges.
- You are willing to follow the study plan and give written permission to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests a new drug combination given before surgery for pancreatic cancer that has not spread. It includes targeted therapy, chemotherapy, and possibly immunotherapy to see if it can shrink tumors and improve outcomes.
This trial tests a new drug (NP137) combined with the chemotherapy FOLFIRINOX before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests whether giving targeted radiation therapy first, followed by a combination chemotherapy (NALIRIFOX), is better than chemotherapy alone for people with pancreatic cancer that is borderline resectable. The goal is to see if the radiation helps shrink the tumor enough to make surgery possible.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.